Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-22,000
Closed -$574K 740
2023
Q4
$574K Sell
22,000
-1,234,344
-98% -$28.2M ﹤0.01% 648
2023
Q3
$641M Buy
1,256,344
+1,236,344
+6,182% +$31M 4.54% 3
2023
Q2
$469K Buy
+20,000
New +$339K ﹤0.01% 679
2022
Q1
Sell
-51,615
Closed -$1.48M 852
2021
Q4
$1.48M Sell
51,615
-72,385
-58% -$2.36M 0.01% 603
2021
Q3
$4.98M Buy
124,000
+74,000
+148% +$3.31M 0.03% 402
2021
Q2
$2.18M Hold
50,000
0.01% 571
2021
Q1
$1.91M Hold
50,000
0.02% 530
2020
Q4
$1.98M Sell
50,000
-248,800
-83% -$10.2M 0.02% 542
2020
Q3
$12.5M Sell
298,800
-114,200
-28% -$5.22M 0.12% 193
2020
Q2
$17.4M Buy
413,000
+289,000
+233% +$8.87M 0.18% 138
2020
Q1
$4.67M Hold
124,000
0.05% 362
2019
Q4
$4.78M Buy
+124,000
New +$4.66M 0.05% 369

Other funds holding XP

Candriam SCA's XP Position: Q1 2024 in Review

Candriam SCA sold out of XP (XP) in Q1 2024, closing a stake of 22,000 shares — an estimated $574K sold.

Candriam SCA first reported a position in XP in Q4 2019 and held it in 12 quarters. The position peaked at $641M in Q3 2023. 298 funds tracked by Wall St. Rank hold XP as of Q1 2024.

  • Candriam SCA reported no remaining XP position as of Q1 2024 after selling out during the quarter.
  • Candriam SCA sold 22,000 XP shares in Q1 2024, an estimated $574K.
  • Candriam SCA first reported a position in XP in Q4 2019 and held it in 12 quarters.
  • Candriam SCA's XP position peaked at $641M in Q3 2023.
  • 298 funds tracked by Wall St. Rank held XP as of Q1 2024.

Based on Candriam SCA's 13F filing for Q1 2024, filed 6 May 2024.